Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Sector news
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  11:39:57 2023-02-03 am EST
85.14 EUR   -1.88%
02/03Health Care Edge Lower After Solid Earnings -- Health Care Roundup
DJ
02/03SANOFI : Goldman Sachs reiterates its Buy rating
MD
02/03French Bourse Close Higher Friday as Private Sector Activity Remains Stable
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Sector news Other Pharmaceuticals
02/03Wells Fargo Adjusts Eli Lilly's Price Target to $360 From $375, Maintains Equal Weight ..
MT
02/03Wells Fargo Adjusts Merck & Company Price Target to $120 From $125, Maintains Overweigh..
MT
02/03European Equities Move Modestly Higher Friday, But Poised to End Week Lower
MT
02/03Truist Securities Adjusts Price Target on Merck & Company to $118 From $106, Maintains ..
MT
02/03Morgan Stanley Adjusts Price Target on Eli Lilly to $455 From $440, Maintains Overweigh..
MT
02/03Morgan Stanley Adjusts Price Target on Merck & Company to $99 From $100, Maintains Equa..
MT
02/03ROCHE HOLDINGS AG : Credit Suisse maintains a Buy rating
MD
02/03AlphaValue/Baader Europe Lowers Price Target on Roche, Upgrades Recommendation to Buy F..
MT
02/03SVB Securities Adjusts Merck & Company's Price Target to $122 From $120, Maintains Outp..
MT
02/03Merck Says Trial of Keytruda and Chemotherapy to Treat Endometrial Cancer Meets Primary..
MT
02/03Merck's Keytruda Meets Main Endpoints in Endometrial Carcinoma Study
DJ
02/03Merck Announces Phase 3 NRG-GY018 Trial Evaluating Keytrudav
CI
02/03ROCHE HOLDINGS AG : Deutsche Bank keeps a Sell rating
MD
02/02Merck & Co. Flags Lower COVID-19 Drug Sales in FY23
MT
02/02Prospects of Fed's Rate-Hiking Cycle Ending Soon Lifts Equities
MT
02/02Sector Update: Healthcare Stocks Stage Thursday Retreat
MT
02/02Sector Update: Health Care Falls as Investors Chase Growth Sectors
MT
02/02Sector Update: Health Care
MT
02/02Global markets live: ABB, Infineon, Shell, Metlife, Boeing...
MS
02/02Eli Lilly Down Over 6%, on Pace for Largest Percent Decrease Since March 2021 -- Data T..
DJ
02/02European Equities Move Lower Following ECB Rate Hike
MT
02/02Trending : Roche Guides for 2023 Sales, Earnings Decline on Covid-19 Drop
DJ
02/02Merck Posts Mixed Fourth-Quarter Results, Issues Downbeat Full-Year Earnings Outlook
MT
02/02Transcript : Eli Lilly and Company, Q4 2022 Earnings Call, Feb 02, 2023
CI
02/02Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
MT
02/02Eli Lilly Fourth-Quarter Results Decline on Foreign-Exchange Headwinds; Full-Year Earni..
MT
02/02Transcript : Roche Holding AG, 2022 Earnings Call, Feb 02, 2023
CI
02/02Transcript : Merck & Co., Inc., Q4 2022 Earnings Call, Feb 02, 2023
CI
02/02Eli Lilly Reports 12% Net Income Growth in FY22; Lifts FY23 EPS Guidance
MT
02/02Eli Lilly Q4 Non-GAAP Earnings, Revenue Decrease; Raises 2023 Adjusted Earnings Outlook
MT
02/02ROCHE HOLDINGS AG : Jefferies gives a Neutral rating
MD
02/02Merck Q4 Adjusted Earnings Slip, Sales Increase; Issues 2023 Outlook
MT
02/02NOVO NORDISK : Credit Suisse remains Neutral
MD
02/02GUIDANCE: (LLY) ELI LILLY AND COMPANY Expects Fiscal Year 2023 EPS Range $8.35 ..
MT
02/02Earnings Flash (LLY) ELI LILLY AND COMPANY Reports Q4 Revenue $7.30B, vs. Street Est of..
MT
02/02Earnings Flash (LLY) ELI LILLY AND COMPANY Reports Q4 EPS $2.09, vs. Street Est of $1.8..
MT
02/02Eli Lilly and Company Revises Earnings Guidance for the Year 2023
CI
02/02Merck & Co., Inc. Provides Earnings Guidance for the Year 2023
CI
02/02GUIDANCE: (MRK) MERCK & CO. Expects Fiscal Year 2023 Revenue Range $57.2B - $58..
MT
02/02GUIDANCE: (MRK) MERCK & CO. Expects Fiscal Year 2023 EPS Range $6.80 - $6.95
MT
02/02Earnings Flash (MRK) MERCK & CO. Reports Q4 Revenue $13.83B
MT
02/02Earnings Flash (MRK) MERCK & CO. Posts Q4 EPS $1.62
MT
02/02NOVO NORDISK : Deutsche Bank gives a Buy rating
MD
02/02ROCHE HOLDINGS AG : Goldman Sachs reaffirms its Buy rating
MD
02/02ROCHE HOLDINGS AG : JP Morgan remains a Sell rating
MD
02/02Roche Names CEO for Pharmaceuticals Unit
MT
02/02Roche Braces for Lower Sales in 2023 as Demand for COVID-19 Products Dwindle
MT
02/02Roche 2022 Sales Grew, But Expects 2023 Decline on Covid-19 Products -- Update
DJ
02/02Roche flags 2023 earnings decline on slump in COVID products
RE
02/02Roche 2022 Sales Grew, But Expects 2023 Decline on Covid-19 Products
DJ
02/02Roche's FY22 Profit Falls as COVID-19 Boost Fades
MT
02/02Roche Holding AG Announces Executive Appointments
CI
02/02Roche Holding AG Provides Group Sales Guidance for the Year 2023
CI
02/02Roche Proposes Dividend for 2023
CI
02/02Formycon Licenses Stelara Biosimilar Candidate to Fresenius Unit
MT
02/01Merck & Co. Says No Direct Evidence of COVID-19 Pill Leading to New Variants
MT
02/01Global markets live: AMD, Amgen, Electronic Arts, PayPal, Snap...
MS
02/01Trending: Novartis's 4Q Net Profit Declines on Poor Drug Performances
DJ
02/01Novo Nordisk Q4 Earnings, Sales Rise; Issues 2023 Outlook; to Start 28 Billion Kroner S..
MT
02/01Novo Nordisk A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 202..
CI
02/01Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DK..
CI
02/01Novo Nordisk A/S Provides Earnings Guidance for the Year 2023
CI
02/01Tranche Update on Novo Nordisk A/S (CPSE:NOVO B)'s ..
CI
02/01Novo Nordisk A/S Reports Earnings Results for the Full Year Ended December 31, 2022
CI
02/01NOVO NORDISK : Jefferies gives a Sell rating
MD
02/01Transcript : Novo Nordisk A/S, 2022 Earnings Call, Feb 01, 2023
CI
02/01NOVO NORDISK : Sell rating from UBS
MD
02/01NOVO NORDISK : JP Morgan maintains a Buy rating
MD
02/01Scancell Holdings Names Jean-Michel Cossery Nonexecutive Chairman
DJ
02/01European shares gain on pharma boost; Fed policy decision on tap
RE
02/01Novo Nordisk Launches $4 Billion Buyback as 4Q Earnings Beat Forecasts
DJ
02/01Novo Nordisk to Launch New DKK28 Billion Share Repurchase Program
MT
02/01Novo Nordisk Reports 16% Jump in FY22 Net Profit on Double-Digit Sales Growth
MT
02/01Novartis Lifts Dividend Despite 4Q Sales, Profit Decline
DJ
02/01Novo Nordisk A/S Proposes Final Dividend for 2022
CI
02/01European Commission Expands Marketing Permit for Roche's Hemlibra
MT
02/01European Commission Approves the Expansion of Roche's Hemlibra European Union Marketing..
CI
02/01Novo Nordisk A/S authorizes a Buyback Plan.
CI
01/31Amgen revenue falls slightly as Lilly COVID deal contributes less
RE
01/31Moody's Says Johnson & Johnson's Court Loss is Negative Credit Development
MT
01/31UBS Adjusts Eli Lilly and Company Price Target to $406 From $420, Maintains Buy Rating
MT
01/31UBS Adjusts Merck & Company Price Target to $108 From $105, Maintains Neutral Rating
MT
01/31Idorsia Files European Marketing Authorization Application For Resistant Hypertension T..
MT
01/31PrescriberPoint, Inc. announced that it has received funding from Eli Lilly and Company..
CI
01/31Carsgen Therapeutics Holdings Limited Announces Collaboration Agreement with F. Hoffman..
CI
01/30Roche's Diagnostics Division Joins Jana Care on Remote Blood Testing Platform
MT
01/30Sector Update: Health Care Stocks' Losses Gain Speed Near Monday Close
MT
01/30Sector Update: Health Care
MT
01/30Johnson & Johnson Worst Performer in the DJIA So Far Today -- Data Talk
DJ
01/30Top Midday Decliners
MT
01/30Jana Care, Inc. to Enter Collaboration with Roche Diagnostics to Develop and Distribute..
CI
01/30Mega-Cap Tech Earnings on Tap; Fed's Policy Leanings Cool US Equity Investors' Risk App..
MT
01/30AstraZeneca Doses First Patient in Phase 3 Study of Datopotamab Deruxtecan to Treat Lun..
MT
01/30Johnson & Johnson's Bankruptcy Petition for Talc Unit Dismissed by Court; Shares Down M..
MT
01/30Johnson & Johnson Stock Falls Amid Reports US Appeals Court Rejected Company's Use of B..
MT
01/30Johnson & Johnson Talc Bankruptcy Case Thrown Out b..
MT
01/30Daiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatment
AN
01/30European Equities Start the Week Modestly Higher Amid German GDP Contraction
MT
01/30Berenberg Bank Adjusts Merck & Company Price Target to $125 From $115, Maintains Buy Ra..
MT
01/30Berenberg Lowers Price Target on Roche, Maintains Buy Recommendation
MT
Upcoming event on SANOFI